Kansler, Emily R.
Dadi, Saïda
Krishna, Chirag
Nixon, Briana G.
Stamatiades, Efstathios G. http://orcid.org/0000-0002-2785-9005
Liu, Ming
Kuo, Fengshen http://orcid.org/0000-0003-1797-2896
Zhang, Jing
Zhang, Xian
Capistrano, Kristelle
Blum, Kyle A. http://orcid.org/0000-0002-2484-385X
Weiss, Kate
Kedl, Ross M. http://orcid.org/0000-0002-9065-7895
Cui, Guangwei
Ikuta, Koichi
Chan, Timothy A.
Leslie, Christina S. http://orcid.org/0000-0002-4571-5910
Hakimi, A. Ari http://orcid.org/0000-0002-0930-8824
Li, Ming O. http://orcid.org/0000-0002-1383-0535
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA243904-01A1, CA008748)
United States Department of Defense | United States Army | U.S. Army Corps of Engineers (KC19008.e001)
Cancer Research Institute (CLIP)
Article History
Received: 14 June 2021
Accepted: 14 April 2022
First Online: 26 May 2022
Change Date: 15 June 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41590-022-01264-5
Competing interests
: MSKCC has filed a patent application with the U.S. Patent and Trademark Office directed toward targeting ILC1 IL-15 signaling for cancer immunotherapy. M.O.L. is an scientific advisory board member of and holds equity or stock options in Amberstone Biosciences and META Pharmaceuticals. All other authors have no competing interests.